Clinical Trial Update: Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ropidoxuridine as a radiosensitizer in newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Idh-wildtype

Drugs mentioned

• Ropidoxuridine (ropidoxuridine)

Snippet

Sponsor: Shuttle Pharmaceuticals, Inc. | Conditions: Glioblastoma, IDH-wildtype | Phase 2 | Status: TERMINATED